The acquisition will help Acelity to expand its advanced wound dressings portfolio, in addition to strengthening its presence in wound healing segment.

Acelity president and CEO Andrew Eckert said: “Crawford’s talented team, highly complementary line of advanced wound dressings, and track record of patient-focused innovation make them a terrific partner to accelerate our global growth.”

Crawford Healthcare is engaged in the development and commercialization of advanced treatments for the care and repair of skin.

The firm produces wound dressing products, including superabsorbent KerraMax Care range, and KerraFoam and KerraCel foam and antimicrobial gelling fiber AWD range.

The acquired portfolio is said to complement Acelity’s existing AWD portfolio, including Promogran Prisma Matrix, Tielle dressing products and Adaptic dressings.

The deal also includes the acquisition of Crawford’s R&D capabilities and manufacturing operations in Cheshire, UK.

Crawford Healthcare chief executive Richard Anderson said: “Becoming part of the world’s largest wound care company will provide us with the scale to optimize our potential within the US, the largest global market and the ability to further access and grow in other international markets with our best-in-class advanced wound care products.”

In February 2017, Allergan acquired Acelity’s regenerative medicine unit, LifeCell, for $2.9bn.

LifeCell produces acellular dermal matrices, which are generally used in breast reconstruction procedures and complex hernia surgeries.

The firm manufactures Alloderm human allograft tissue matrix that can be used in breast reconstruction post-masectomy and Revolve single use high-volume fat grafting device is developed to be used in plastic and reconstructive procedures.

Based in San Antonio of Texas, Acelity provides advanced healing solutions for customers and patients across the care continuum.

KCI, which is a subsidiary of Acelity, supplies wound care products in more than 90 countries across the globe.